Company intelligence / Profile preview

Fan Li

Ningbo, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Fanli Biotechnology (also known as Truelab Biopharmaceutical) is a Chinese biotechnology company specializing in AI-driven drug discovery for autoimmune and inflammatory diseases. Founded in 2023 and headquartered in Ningbo with roots in Wuhan, the company leverages its proprietary AI platform to identify and validate novel therapeutic targets and develop high-affinity monoclonal antibodies. Its lead program focuses on targeting Tumor Necrosis Factor-like Ligand 1A (TL1A) for the treatment of Inflammatory Bowel Disease (IBD) and respiratory conditions. The company has attracted significant investment from major firms including Tencent, Huagai Capital, and Loyal Valley Capital to advance its pipeline of precision medicines.

Therapeutic areas: ImmunologyPulmonologyGastroenterology
Modalities: Monoclonal antibodyAntibodySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Fan Li.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fan Li.

Explore the full profile